Genprex Collaborators Present Positive Preclinical Data for Diabetes Gene Therapy Drug Candidate GPX-002

Genprex's research collaborators presented positive preclinical data for GPX-002, a diabetes gene therapy drug candidate. Studies in Non-Human Primates showed improved glucose tolerance and reduced insulin requirements after infusion of the drug. However, an immune response was induced after discontinuation of immunosuppression, indicating the need for longer IS administration. Researchers are continuing preclinical studies in NHP models of Type 1 and Type 2 diabetes.